Beta Bionics, Inc. BBNX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 52.54% | 57.87% | 53.94% | 67.01% | 97.91% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 52.54% | 57.87% | 53.94% | 67.01% | 97.91% |
| Cost of Revenue | 38.02% | 46.82% | 52.94% | 69.47% | 101.37% |
| Gross Profit | 64.94% | 67.30% | 54.75% | 65.00% | 95.05% |
| SG&A Expenses | 53.82% | 61.06% | 68.19% | 71.45% | 85.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.74% | 50.92% | 55.77% | 67.88% | 80.64% |
| Operating Income | -32.77% | -42.01% | -58.41% | -69.03% | -62.89% |
| Income Before Tax | 0.54% | 6.38% | -33.68% | -40.27% | -34.77% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 0.54% | 6.38% | -33.68% | -40.27% | -34.77% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 0.54% | 6.38% | -33.68% | -40.27% | -34.77% |
| EBIT | -32.77% | -42.01% | -58.41% | -69.03% | -62.89% |
| EBITDA | -31.78% | -41.64% | -58.98% | -71.01% | -64.83% |
| EPS Basic | 70.03% | 79.79% | 77.34% | 51.64% | 40.72% |
| Normalized Basic EPS | 70.03% | 79.79% | 77.34% | 51.65% | 40.72% |
| EPS Diluted | 70.03% | 79.79% | 77.34% | 51.64% | 40.72% |
| Normalized Diluted EPS | 70.03% | 79.79% | 77.34% | 51.65% | 40.72% |
| Average Basic Shares Outstanding | 102.23% | 250.28% | 536.19% | 401.32% | 276.58% |
| Average Diluted Shares Outstanding | 102.23% | 250.28% | 536.19% | 401.32% | 276.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |